Hester Biosciences Limited Releases Performance Snapshot for H1FY19; Sales up by 20%, Profitability up by30%

Deepthi | Myequity news | Date : 29-10-2018 11:50:00 IST

Hester Biosciences Limited announced its quarterly and half yearly financial results for FY19.

Q2 Highlights:

∙Hester has reported a Net Sales of INR 425.42 Million in Q2FY19 as compared to INR 384.79 Million for the previous corresponding period, thereby registering a growth of 11%.
∙Net Profit for Q2FY19 is recorded at INR 99.32 Million as against INR 88.55 Million for the previous corresponding period, thereby registering a growth of 12%.
∙Earnings Per Share for the Q2FY19 is at INR 11.68 as against INR 10.41 for Q2FY18.

H1 Highlights:

∙Hester has reported a Net Sales of INR 808.02 Million in H1FY19 as compared to INR 675.20 Million for the previous corresponding period, thereby registering a growth of 20%.

∙Net Profit for H1FY19 is recorded at INR 196.16 Million against INR 150.44 Million for the previous corresponding period, thereby registering a growth of 30%.
∙Earnings per Share for H1FY19 is at INR 23.06 as against INR 17.68 for the H1FY18.

ABout Hester Biosciences Limited:

Hester Biosciences Limited (HBL) is a publicly traded Indian company headquartered in Ahmedabad, Gujarat, India. Hester is an animal and poultry vaccines manufacturing Company with plants situated in Gujarat and Nepal. The company currently has a 30% share of the poultry vaccines market in the country. This makes Hester India's second largest poultry vaccine manufacturer. Hester is also the first commercial manufacturer of Goat pox vaccine in India and manufactures PPR vaccines from both, Nigerian and Sungri strains.


More from Myequity